Investments and investor services
FTSE 100 closes in red, despite US market turnaround
In London, the FTSE 100 closed down around 29 points at 7,252
Company
GSK PLC
LON:GSK
GSK PLC will be a fully focused biopharma company following the demerger of its world-leading consumer healthcare business, Haleon, in July 2022. The company will prioritise innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease.
743 stories · page 6 of 8
Archive
Another day, another bank reporting results - Barclays the next up to the oche
Day ahead includes a swathe of FTSE 100 results, including from the likes of Barclays PLC, British American Tobacco PLC, BAE Systems PLC, and Centrica PLC
Reckitt Benckiser's bid to buy Pfizer unit a step in the right direction, says JP Morgan
Shares in Reckitt have continued to decline after Monday's disappointing results as JP Morgan cut its 2018 earnings guidance and target price
Investments and investor services
FTSE 100 makes up some ground to close a tad lower as earnings disappoint
The minister responsible for Britain's exit from the EU, David Davis said the UK would lead a “global race to the top"
Reckitt Benckiser Group expects a return to growth this year
The group returned to like-for-like revenue growth in the fourth quarter..
Archive
Banks to feature strongly in deluge of blue chip earnings, including Lloyds, RBS, Barclays
Week ahead includes a deluge of blue chip results, notably from the banking sector, including numbers from HSBC PLC, Barclays PLC, Lloyds Banking Group PLC, and Royal Bank of Scotland PLC
GlaxoSmithKline winning over City number crunchers
Is the market being too negative about the prospects for the HIV franchise and generic competition to its best-selling asthma treatment, Advair?
GSK sues US rival Gilead Sciences for alleged HIV drug patent infringement
GSK’s one pill, once daily treatment was approved back in November, while Gilead’s drug got the green light from the US FDA on Wednesday
GSK warns 2018 earnings hinge on generic competition to its blockbuster Advair inhaler
If a generic competitor comes to market this summer as expected, GSK said earnings will fall by between 0-3%, while if a competitor isn’t forthcoming, earnings will rise by 4-7%
FTSE 100 closes strongly higher as markets stabilise
The UK blue chip index closed up 138 at 7,279 - above the day’s peak of 7,255.
Archive
Rio Tinto expected to reiterate policy of value over volume
Rio Tinto is expected to carry on returning piles of cash to shareholders but some people think a dividend cut at Glaxo is on the cards
FTSE 100 succumbs to global profit-taking, closes firmly in red
The UK blue chip index closed down 108.45 points at 7.334, which had been the session low
Archive
Bank of England rate decision eyed, plus numbers from blue chips BP and Glaxo in coming week
After November's hike, another UK rate rise is unlikely this month, although some Bank of England MPC members may vote for a rise after a unanimous vote in December
NeuroMetrix booms as it enters into strategic collaboration with healthcare giant GSK
GSK is paying Neurometrix US$5mln up front plus up to US$21.5mln in milestone payments to acquire the exclusive ownership of the Quell technology
Barclays cites progress in HIV and new shingles vaccine as it turns bullish on GSK
Analyst Emmanuel Papadakis has upgraded GSK to ‘overweight’ and hiked his price target to £16.50, claiming that any risks are now priced in, while progress has been made in HIV and shingles
GSK edges higher as it releases “promising” new data from phase I/II blood cancer trial
In the dose expansion phase of its DREAMM-1 phase I/II study of GSK2857916, the antibody-drug conjugate demonstrated a 60% response rate and median progression-free survival of 7.9 months
GSK’s latest phase III shingles trial offers hope to stem cell transplant patients
People who have undergone stem cell transplants typically have weaker immune systems, which makes them more susceptible to viruses such as shingles
GSK’s ViiV Healthcare kicks off enrolment of big phase III HIV trial in Africa
The trial will evaluate the effectiveness of an injectable HIV drug, administered only once every two months, in sexually active women
Investments and investor services
Parallel Media and Physiomics lead small cap market gainers
Some of the biggest risers and fallers in London on Wednesday
Investments and investor services
FTSE 100 closes lower as pound firms amid Brexit bill breakthrough
London's blue-chip index closed the day lower but retailers and housebuilders did well, oh, and there was some Brexit news...
UBS reckons GSK is a ‘buy’, citing weak share price and secure dividend
Uncertainty surrounding the trajectory of GSK’s ViiV Healthcare HIV business justifies a discount argues UBS analyst Michael Leutchen, but he reckons the valuation now reflects that
GSK steals a march on rivals as its two drug, one pill HIV treatment gets green light from FDA
Juluca – as the treatment is known – is made by GSK’s majority-controlled ViiV Healthcare and is the first such drug to be approved by US authorities
New HIV and lung drugs help boost GSK’s Q3 sales but investors hoped for more
The strong demand for Tivicay and Relvar, among others, justifies new boss Emma Walmsley’s decision to narrow the drugmaker’s focus on HIV and respiratory medicines
Investments and investor services
FTSE 100 closes over 1% lower as sterling spikes
The UK blue chip index closed down 1.05% to 7,447 as the pound strengthened after better-than-forecast UK GDP
Archive
Lloyds Banking looking to put its trials behind it
PPI, the HBOS acquisition and now the prospect of a rate rise hitting the mortgage market; it's all a bit of a trial for Lloyds
GSK gets approvals for 'bubble boy' syndrome gene therapy in UK and shingles vaccine in US
The UK healthcare cost regulator has approved GSK's gene therapy for so-called 'bubble boy' syndrome while the US FDA has approved its shingles vaccine
Lloyds, Barclays and RBS under the microscope with release of third quarter earnings
The week ahead includes third quarter earnings from Lloyds, Barclays and RBS along with trading updates from Shire, IAG and GSK
Koovs jumps on partnership deal with online clothing retailer N Brown
A look at some of the biggest risers and fallers today in London
FTSE 100 closes in negative territory despite resource stock gains
The UK blue chip index closed at 7,526, well below the session peak of 7,557.00 and close to the day’s low of 7,531.48
GlaxoSmithKline gets 'positive opinion' from EMA panel for three-in-one inhaled COPD treatment
The once-a-day triple inhaler combines the drugs fluticasone furoate, umeclidinium and vilanterol and will have a proposed brand name of Trelegy Ellipta
Shire, AstraZeneca and GSK in the red as JP Morgan looks at risks facing pharmaceutical sector
Shire remains the "standout stock" as it has an "extremely compelling valuation”, according to JP Morgan
GSK asthma study results published in medical journal and presented at industry meeting
A study of GSK's Relvar Eillipta treatment showed an improvement in symptoms of asthma sufferers
FTSE 100 trims losses
The FTSE 100 retreated as investors worry about Hurricane Irma, while mixed economic statistics raised fresh concerns over the UK economy.
Analyst thinks Vectura share price drop may not just be due to bigger pre-tax loss
Mike van Dulken, head of research at Accendo Markets said the share price reaction “may in fact be due to a downgraded Risk & Uncertainties statement, buried half way through the report before the financial statements"
FTSE 100 plunges on North Korea fears
The FTSE 100 finished 108 points lower at 7,390, about 13 points above its intra-day low
United Therapeutics opens 10% higher as GlaxoSmithKline is named as a potential bidder for the group
Sources are cited as saying the bidding could go as high as US$200 a share, valuing the business at US$8.7bn
GlaxoSmithKline shares ease as new boss Walmsley looks to streamline pharma business
More than 30 pre-clinical and clinical programmes will be stopped, divested or partnered out, it emerged
GlaxoSmithKline boss Walmsley unveils restructuring plan; earnings downgrade hits shares
Not entirely unexpected was the trimming of full-year earnings guidance. That said, it precipitated a modest sell-off with the stock down 1.6% in afternoon trade, wiping £1bn from the value of GSK.
FTSE 100 closes 17.5 higher as ITV plc takes podium
The blue chip index has more than made up for the miserable start to the week with a solid showing both yesterday and today...
Archive
Glaxo hoping not to make a right Horlicks of combating generics challenge
The recently-announced sale of Horlicks may be the sign of an increased focus on the drugs pipeline
Archive
Lloyds and Barclays to dominate manic week of corporate earnings
Week ahead: Lloyds, Barclays, AstraZeneca, GlaxoSmithKline, Sky, Reckitt Benckiser
FTSE 100 ends lower but European shares fare worse
London stocks were on the front foot this morning, but they quickly retreated this afternoon...
Archive
Much to ponder for GlaxoSmithKline's new boss
Next week is a big one for Emma Walmsley, GlaxoSmithKline’s newish chief executive.
GSK confirms plans to sell Horlicks in the UK and cut 320 jobs as it prioritises drugs business
GSK's new chief executive wants the company to focus on its pharmaceuticals business as it comes under increased pressure from generic drug competitors
Investments and investor services
FTSE 100 finishes over 40 points ahead with housebuilders in support
The blue chip index closed up 40.69 at 7,430 on the day
Worldpay takeover may be first of many as US firms go Brexit bargain hunting
ITV, Burberry and GlaxoSmithKline could face potential bids from international rivals as a weaker pound stokes interest in a number of UK-based firms
GlaxoSmithkline - Broker downgrade wipes £1.4bn from the value of Europe's largest drug maker
Citi has gone to ‘neutral’ from ‘buy’ on GSK shares, which it reckons are worth £17 each
Investments and investor services
FTSE 100 drifts off highs as US stocks make weak start
The FTSE 100 index was closed up 10.37 at 7,367 on Wednesday
US stocks cruise to higher finish but Tesla reverses
Wall Street shares closed mixed , but the Dow Jones added 129 in the truncated session.
Frontier IP gets boost as portfolio company Exscientia agrees AI collaboration with GlaxoSmithKline
Exscientia will use its artificial intelligence enhanced platform to identify pre-clinical drug candidates for up to 10 disease-related targets
GlaxoSmithKline and AstraZeneca among drug stocks buoyed by Trump’s healthcare plans
The Republicans are looking to repeal Obamacare as well as trying to ease regulatory pressures in the industry
Liberum Capital downgrades European pharma sector to 'neutral', but remains positive on GlaxoSmithKline and AstraZeneca
The broker has been bullish on the sector since November’s US elections, in which time the sector has advanced 20%, or 12% in relative terms.
FTSE 100 rises as May's new government is DUPed
Despite the worst case scenario in the General Election, the FTSE 100 rose strongly
GlaxoSmithKline makes submissions for key HIV single-tablet treatment to both the EMA and the US FDA
The submission is for a combination of dolutegravir, developed by ViiV Healthcare and Tivicay, and rilpivirine, developed by Edurant, and Janssen Sciences Ireland UC
GlaxoSmithkline: Long-term value emerging, says broker
Berenberg’s share price target moves to £18.85 from £18.50, prompting a recommendation upgrade to ‘buy’ from ‘hold’.
Hikma's shares plunge after cutting full year revenue forecast on asthma drug launch delay
Hikma Pharmaceuticals has confirmed that it does not expect to launch its generic version of Advair this year
Footsie ends the week in profit as US stocks extend rally
Concerns over "the Donald" appear to be easing, and investors took the opportunity to return to equity markets
Hikma Pharmaceuticals hit by downgrade prompted by Advair delay fears
The catalyst for the change is the likely delay to the introduction of a low-cost, copycat version of GlaxoSmithKline’s (LON:GSK) inhaled asthma drug, Advair, being developed by the company.
BP ticks higher as shareholders back CEO's reduced pay at AGM
A look at some of the biggest London-listed risers and fallers today
Neil Woodford returns banks to his portfolio for first time since 2003 with Lloyds investment
Woodford Investment Management said it sees Lloyds as a "well managed bank" with the ability to pay a "very healthy and growing" level of dividend
FTSE 100 closes at record high after third-straight week of gains
At the close, the UK blue chip index was up 0.7%, or 48.8 points at 7,435.4, not far below its all-time record of 7,447.0
Global Invacom shares rocket after it posts a swing to a net profit
A look at some of the biggest London-listed risers and fallers today
Investments and investor services
FTSE 100 finishes little changed after "Super Thursday" underwhelms
The Footsie was back in black - but only just - thanks to precious metals miners
Archive
HSBC may struggle to match rivals
HSBC is the last of the big four banks to report with more uncertainty over the outcome than for its UK-centric rivals.
GlaxoSmithKline shares weak despite being on track to deliver its financial targets for 2017 under new boss Emma Walmsley
The FTSE 100-listed firm said its adjusted earnings per share rose by 31% to 25.0p in the quarter to March 31, beating forecasts for 24.5p
FTSE 100 posts positive finish with all eyes on Trump
The FTSE 100 closed at 7,288 as traders look ahead to Donald Trump's tax plans
Archive
BHP in need of response after activist throws down gauntlet
Day ahead: BHP Billiton, GlaxoSmithKline, Proactis...
FTSE 100 closes over 2% higher as France vote cheers
The FTSE 100 closed 150 points, or 2.11% higher, as investors welcomed Macron's result in the first round of France's presidential election
Archive
BHP Billiton and banks dominate big week for blue chips
Week ahead: Huge for blue chip announcements with four high street banks, the UK’s two pharma giants, mining titans Anglo and BHP and restaurant to coffee chain Whitbread just a few of those updating.
GSK, AT&T and Verizon join advertising boycott on Google over extremist content
Google's promise to crack down on adverts from appearing alongside extremist content has failed to reassure clients
Archive
UK unemployment sees surprise fall, but average earnings growth slowing
The jobless rate fell to 4.7%, down from 4.8% last month, marking its lowest level since the summer of 1975, with economists having expected no change
Barclays Capital analysts "resoundingly positive" on pharma stocks; AstraZeneca top pick
“Our clear preference is for specialty-focus and growth in the context of a strong-catalyst driven thematic or deep value,” Barclays said in a brief note to clients.
Drugs-crazed shoot-out: which investment is best out of Astra, Glaxo and Shire?
We’ve had the final results from Holy Trinity of the UK pharma industry ... which is the one to back?
Investments and investor services
Day Ahead: Shire the big draw with sales of new drug closely monitored
Shire’s results Thursday will update on how 2016 ended as it provides commentary and numbers on the fourth quarter, which will be consolidated to provide full-year numbers too.
GSK announces positive study results for HIV treatment
GSK says the results of its phase three study of its HIV treatment may change our understanding of how the virus can be managed.
Archive
Week ahead: Shire continues pharma newsflow; Rolls-Royce results also key
Shire will complete the fourth-quarter results announcements from the FTSE 100-listed pharma giants following numbers from Astra and Glaxo
Investments and investor services
FTSE ends higher after tax cut pledge powers Wall St rally to record levels
FTSE 100 shares closed higher on Thursday in tandem with a US equity rally after President Donald Trump announced “phenomenal” corporate tax reform Wall Street had been waiting for with bated breath
US stocks recover from losses as analysts focus on surprise gasoline supply drop
US stocks recovered from intraday losses to end higher on Wednesday after analysts focused on a fall in gasoline inventories rather than a spike in oil supplies
Glaxo braces itself for £1bn Advair hit
Core earnings per share was 102.4p, at the top end of guidance for the year, but current year guidance was heavily caveated
Archive
Day Ahead: Sterling's slump could mask drab performance from Glaxo
Glaxo is the next pharmaceuticals giant to update the market and it will probably be a familiar story of increased competition from generic versions of its blockbuster drugs.
Archive
Week ahead: BP and Glaxo to continue trading trends for oil and drug giants
BP could please on Thursday as its recent quarterly updates have proved a little disappointing. GlaxoSmithKline will unveil its numbers Wednesday.
FTSE 100 shares sink as pound ascends on Trump disquiet
FTSE 100 stocks fell further below 7200 on Monday after sterling gained strength against the US dollar in the aftermath of President Donald Trump's inauguration speech
GlaxoSmithKline could receive further Brexit boost, says broker
That at least is the opinion of the respected pharma team at Jefferies, which raised its valuation of shares Europe’s largest drugs firm.
FTSE 100 shares hit 11th successive record high as sterling dips
FTSE 100 shares did it again on Thursday – the 11th successive record high close – as turbulence in sterling finally gave in to a further steady decline and helped push stocks higher. All except retailers, that is
Zak Mir tips three big names to do well in 2017
Mir has gone for giants in the oil, pharma and broadcasting sectors
Brexit and Trump key to how 2017 unfolds
Richard Hunter is keeping tabs on AstraZeneca, GSK and ITV as we head into 2017
GlaxoSmithKline’s fast-growing HIV drug business gets another boost
Glaxo has developed the new two-drug cocktail through its majority-owned ViiV Healthcare joint venture, in which US firm Pfizer and Japan’s Shionogi also hold stakes.
Investments and investor services
FTSE 100 ends above 7,000 for first time since late October
FTSE 100 shares closed back above 7,000 on Friday for the first time since late October
AstraZeneca top pick under UBS's new valuation method
The conventional forecasting tool-box is broken says the Swiss broker
Archive
Trending - fines, HSBC, JP Morgan, Pfizer and bird flu
A look at some of the big, trending topics on Wednesday
Five reasons to buy AstraZeneca
The general consensus is that the decline in AstraZeneca’s share price now represents a good buying opportunity
GlaxoSmithKline's shingles vaccine filed in Europe
Most sufferers are afflicted with a rash, but in the severest cases the disease can cause blindness and intense pain.
GlaxoSmithKline and Innoviva celebrate early FDA submission of COPD treatment
The closed triple combination therapy comprises three medicines delivered once-daily in GSK's Ellipta dry powder inhaler.
Risers and fallers: Fresnillo glistens, while Tate's in a state
Some of the main news-driven share price changes at 3.30pm.
Drugs stocks boosted by Clinton defeat
Markets have reacted badly to Trump's electoral victory, but some sectors have benefited
Archive
Brokers: UK pharma giants in good shape if Clinton wins says Citigroup
“From a legislative angle, we continue to prefer names with either limited part D exposure [US Medicare] or heavier contribution of non-pharma assets."
GlaxoSmithKline medicine goes down well in City
Deutsche analyst Richard Parkes said the market beating sales were mainly down to the group's strong sales of vaccines, notably for flu - Bexsero, Boostrix and Synflorix.